{
    "organizations": [],
    "uuid": "a7f807997cbb13c1acebe7a9ce77758ba5580c3d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-opgen-says-entered-agreement-to-us/brief-opgen-says-entered-agreement-to-use-thermo-fishers-real-time-pcr-technology-in-cos-new-acuitas-tests-idUSFWN1Q30YS",
    "ord_in_thread": 0,
    "title": "OpGen Says ‍Entered Agreement To Use Thermo Fisher's Real-Time PCR Technology In Co's New Acuitas Tests​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - Opgen Inc:\n* OPGEN INC - ‍ENTERED GLOBAL SUPPLY AGREEMENT TO USE THERMO FISHER SCIENTIFIC‘S REAL-TIME PCR TECHNOLOGY IN COMPANY‘S ACUITAS AMR GENE PANEL TESTS​\n* OPGEN INC - ‍PLANNING CLINICAL TRIALS TO SUPPORT REGULATORY SUBMISSIONS FOR BROADER CLINICAL USE IN PATIENTS WITH COMPLICATED URINARY TRACT INFECTIONS​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T20:39:00.000+02:00",
    "crawled": "2018-02-14T12:37:39.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "opgen",
        "inc",
        "opgen",
        "inc",
        "global",
        "supply",
        "agreement",
        "use",
        "thermo",
        "fisher",
        "scientific",
        "pcr",
        "technology",
        "company",
        "acuitas",
        "amr",
        "gene",
        "panel",
        "opgen",
        "inc",
        "clinical",
        "trial",
        "support",
        "regulatory",
        "submission",
        "broader",
        "clinical",
        "use",
        "patient",
        "complicated",
        "urinary",
        "tract",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}